RayzeBio, a leading company in the field of radiopharmaceuticals, has recently received a buy rating from William Blair.
In their analysis, William Blair highlights RayzeBio’s potential to become a leader in the radiopharmaceutical industry. The investment bank specifically mentions RYZ101, the company’s lead therapy candidate currently in Phase 3 testing for neuroendocrine tumors. With a “high chance of success,” RYZ101 also has the potential for application in treating small-cell lung cancer, which could further enhance the success of RayzeBio’s RYZ101 franchise. Additionally, William Blair notes that RYZ101 could become the first approved actinium-225-based radiopharmaceutical.
William Blair also emphasizes the strategic advantage of RayzeBio’s in-house production capabilities. While maintaining external supply agreements, the company’s ability to produce and radiolabel actinium-225 internally adds redundancy and ensures a consistent source of radiopharmaceuticals for both clinical and commercial purposes. This distinguishing feature sets RayzeBio apart from other clinical-stage radiopharmaceutical companies.